On the morning of the 2nd, while the domestic stock market (KOSPI and KOSDAQ) showed weakness due to overall contraction in investor sentiment, Sillajen is drawing market attention and maintaining a slightly upward trend.

As of mid-session on this day, Sillajen was traded at 2,340 won, up 20 won (0.86%) from the previous trading day, recording a modest gain. The defense of its stock price is interpreted to be driven by expectations surrounding the recently signed new business partnership.

Sillajen recently signed a supply and co-marketing agreement with Shinshin Pharmaceutical for ethical (ETC) intravenous (IV) solutions. Specifically, Sillajen will supply four types of ETC IV solutions to Shinshin Pharmaceutical, while Shinshin Pharmaceutical will be exclusively responsible for marketing and sales to new channels that are not existing customers of Sillajen. The contract period between the two companies is up to five years and can be extended through mutual agreement.

The market is positively evaluating the fact that Sillajen is diversifying its business foundation by expanding its distribution and sales cooperation for ethical pharmaceuticals, in addition to its existing anticancer drug development.

[This article was written with the assistance of AI. This article is not a solicitation for investment, and the final judgment and responsibility for investment rest with the investor.]